Provider Briefing: Cefuroxime Supply in 2026

Cefuroxime remains a workhorse antibiotic in outpatient and inpatient settings — a reliable second-generation cephalosporin with broad-spectrum activity and a favorable safety profile. However, ongoing supply dynamics have created challenges for both the injectable and oral formulations. This briefing summarizes the current state of Cefuroxime availability, prescribing considerations, and practical resources for helping your patients access treatment.

Supply Timeline and Current Status

Injectable Cefuroxime Sodium (Zinacef)

Cefuroxime Sodium injection has appeared on the ASHP drug shortage list. Key details:

• Hikma Pharmaceuticals experienced supply disruptions affecting 750 mg and 1.5 g vials. The company did not publicly disclose a specific root cause.
• Sagent Pharmaceuticals has maintained production and represents the primary available supply of injectable Cefuroxime.
• Hospital availability has been inconsistent, particularly for the 1.5 g presentation used in surgical prophylaxis.
• No confirmed resolution date has been announced by Hikma as of early 2026.

Oral Cefuroxime Axetil (Ceftin)

The oral formulation — available as 250 mg and 500 mg tablets and as oral suspension (125 mg/5 mL, 250 mg/5 mL) — is manufactured by multiple generic companies and is not in a formal FDA shortage. However:

• Retail pharmacy stocking of Cefuroxime can be inconsistent, particularly at chain pharmacies that use just-in-time inventory models.
• Seasonal prescribing surges (respiratory infection season) can temporarily deplete local supply.
• The injectable shortage may increase prescribing of oral Cefuroxime for step-down therapy, adding demand pressure on the retail supply.

Prescribing Implications

The supply situation creates several considerations for prescribers:

Surgical Prophylaxis

For facilities relying on Cefuroxime Sodium for perioperative prophylaxis, the injectable shortage may require substitution. Common alternatives include:

• Cefazolin — first-generation cephalosporin, preferred for many surgical prophylaxis protocols
• Ceftriaxone — third-generation, broader spectrum, once-daily dosing

Consult your facility's antibiotic stewardship committee and P&T guidelines for approved substitutions.

Outpatient Prescribing

When prescribing oral Cefuroxime for outpatient infections, be aware that patients may face difficulty filling the prescription. Proactive steps include:

• Advising patients to check availability before leaving the office — tools like Medfinder for Providers can help
• Considering whether equally effective alternatives (see below) may be more readily available
• Specifying both tablet and suspension as acceptable forms, if clinically appropriate, to give the pharmacy more options

IV-to-Oral Transition

For inpatients transitioning from IV to oral therapy, oral Cefuroxime Axetil remains a logical step-down from IV Cefuroxime Sodium. If oral Cefuroxime is unavailable at the patient's discharge pharmacy, consider prescribing Amoxicillin-Clavulanate or Cefdinir as alternatives for the outpatient portion of therapy.

Availability Picture: Where Patients Can Find Cefuroxime

Patient-reported data and pharmacy surveys indicate:

• Independent pharmacies tend to carry broader antibiotic inventories and often have Cefuroxime in stock when chains do not.
• Hospital outpatient pharmacies typically maintain supply for discharge prescriptions.
• Chain pharmacies (CVS, Walgreens, Rite Aid) may have inconsistent stock, particularly in rural or lower-volume locations.

Direct patients to Medfinder for Providers to check real-time pharmacy availability by zip code, reducing the burden on your office staff to make multiple pharmacy calls.

Cost and Access Considerations

Cefuroxime is a generic medication with generally favorable economics:

• Insurance: Covered on most formularies as Tier 1 or Tier 2. Prior authorization and step therapy are rarely required.
• Cash price: $50-$171 for a standard oral course (14 tablets, 500 mg) without insurance.
• Discount programs: GoodRx, SingleCare, and other platforms offer Cefuroxime for $11-$15 per course.
• Patient assistance: As a generic-only medication, no manufacturer copay cards exist. NeedyMeds (needymeds.org) and RxAssist (rxassist.org) can help uninsured patients find discount programs.

For patients expressing concern about cost, direct them to our patient-facing resource: How to save money on Cefuroxime in 2026.

Tools and Resources for Your Practice

• Medfinder for Providers — real-time pharmacy stock lookup for Cefuroxime and other medications
• ASHP Drug Shortage Resource Center — current shortage status and manufacturer updates for Cefuroxime Sodium injection
• FDA Drug Shortage Database — official federal reporting on drug shortages
• Antibiotic Stewardship Guidelines — IDSA/ATS guidance on appropriate empiric antibiotic selection

Therapeutic Alternatives at a Glance

When Cefuroxime is unavailable or clinically interchangeable, consider these alternatives based on indication:

• Amoxicillin-Clavulanate (Augmentin) — similar spectrum, excellent for sinusitis, otitis media, and respiratory infections. Well-tolerated. Generic widely available ($10-$25 with coupon).
• Cefdinir — third-generation oral cephalosporin. Once or twice daily dosing. Good for ENT and respiratory infections. ($15-$30 with coupon).
• Cephalexin (Keflex) — first-generation cephalosporin. Narrower spectrum but excellent for skin/soft tissue infections and UTIs. Very affordable ($4-$10 with coupon).
• Azithromycin — macrolide class. Useful for penicillin/cephalosporin-allergic patients. 5-day course. Does not cover UTIs or Lyme disease.

A detailed patient-facing comparison is available at alternatives to Cefuroxime.

Looking Ahead

The pharmaceutical supply chain continues to evolve, with increased attention from the FDA and Congress on drug shortage prevention. For Cefuroxime specifically:

• Multiple generic manufacturers maintain oral production lines, making a sustained oral shortage unlikely.
• The injectable shortage depends on Hikma's manufacturing recovery and potential entry of additional suppliers.
• Telehealth expansion has increased prescribing access for common infections treatable with Cefuroxime, potentially adding incremental demand.

Final Thoughts

Cefuroxime remains an effective and appropriate choice for many common infections. The current supply challenges are manageable with awareness and planning. By checking availability proactively, communicating with patients about potential pharmacy issues, and having alternative antibiotic strategies ready, you can minimize treatment delays. Medfinder for Providers is a free tool that can integrate into your workflow to help patients find their medications faster.